PROCEPT BioRobotics Now Faces Two Shareholder Suits Over Handpiece Sales Claims
The surgical-robot maker's quarterly report details a class action and a derivative suit, with losses it says it cannot estimate.
PROCEPT BioRobotics, which makes robots that remove prostate tissue with a waterjet, now describes a securities class action and a shareholder derivative suit in its quarterly report filed Wednesday. Both center on alleged misstatements about handpiece sales, procedure volumes and discounting.
Two complaints in San Francisco's federal court
The class action was filed July 24, 2026 in federal court in Northern California. The Operating Engineers Construction Industry and Miscellaneous Pension Fund is the plaintiff, representing investors who purchased shares from February 28, 2024 through February 25, 2026.
Investors allege they were misled, including on financial guidance. They seek unspecified compensatory damages plus legal costs from the company and certain current and former executive officers.
The derivative suit, Chen v. Zadno, followed on September 15, 2026 in the same court. Current and former executives and directors are sued, with the company a nominal defendant, so any recovery would go to the company. It rests on substantially similar allegations and asserts claims under Section 14(a) of the Exchange Act, breach of fiduciary duty and related state-law claims. It also demands governance reforms.
From no material proceedings to a warning
The prior quarter's report saw no legal proceedings management expected to have a material adverse effect. Now it warns that losing this matter "could have a material adverse effect" on its business, results of operations or financial condition.
The company says it has meritorious defenses and intends to defend the case vigorously. It says the litigation is early-stage and any loss is not yet estimable.
A growing business behind the suits
PROCEPT sells the AquaBeam and HYDROS robotic systems, each of which uses a single-use handpiece for every procedure, so handpiece volume and pricing sit near the core of its revenue. Revenue rose 18% to $98.3 million in the third quarter, and U.S. handpieces sold ran at about 106% of U.S. procedures, according to the earnings release. The company reiterated full-year revenue guidance of $390 million to $410 million.
The quarter's net loss was $26.5 million, against $21.4 million a year earlier. Gross margin edged up to 66% from 65%, a gain the filing attributes primarily to $3.2 million of tariff refunds. Cash stood at $218.4 million, and the install base reached 1,095 systems, including 858 in the U.S.
The filing also says the company reorganized its Aquablation sales team to focus on driving system utilization by urologists.
Chief Executive Larry Wood said WATER IV, the company's prostate cancer trial, is on track to present data in the first half of 2027.
Sources
- 10-Q Filing — PROCEPT BioRobotics (PRCT) — SEC EDGAR
- 10-Q Filing — PROCEPT BioRobotics (PRCT), Q2 FY2026 filed 2026-08-05 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, prct_q32026earningsrelease.htm) — PROCEPT BioRobotics, filed 2026-11-04 — SEC EDGAR
- Procept GAAP EPS of -$0.46 misses by $0.07, revenue of $98.3M misses by $2.22M (PRCT:NASDAQ) | Seeking Alpha — seekingalpha.com
- PROCEPT BioRobotics Reports Third Quarter 2026 Financial — globenewswire.com
- Attention Long-Term Shareholders of Aardvark Therapeutics, — globenewswire.com